




Searching News Database: NEUROCHEM
HSMN NewsFeed - 6 Aug 2018
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 25 Jul 2013
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 13 Mar 2008
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
HSMN NewsFeed - 14 Dec 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem announces important initiatives to provide medical and health benefits to patients
HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
HSMN NewsFeed - 17 Jul 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
HSMN NewsFeed - 11 Apr 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
HSMN NewsFeed - 2 Nov 2006
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
Tramiprosate (ALZHEMED(TM)) Phase II Clinical Results Published in Neurology
HSMN NewsFeed - 16 Oct 2006
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
HSMN NewsFeed - 20 Jun 2006
U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's Disease
U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's Disease
Additional items found! 31

Members Archive contains
31 additional stories matching:
NEUROCHEM
(Password required)
NEUROCHEM
(Password required)